{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:25:13Z","timestamp":1793874313473,"version":"4.6.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,11]],"date-time":"2027-08-11T00:00:00Z","timestamp":1817942400000},"content-version":"am","delay-in-days":314,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R21 DA062400"],"award-info":[{"award-number":["R21 DA062400"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neulet.2026.138703","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:09:04Z","timestamp":1785942544000},"page":"138703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Xylazine reduces methamphetamine-induced hyperlocomotion in rats through \u03ba-opioid and \u03b12-adrenoceptor mechanisms"],"prefix":"10.1016","volume":"885","author":[{"given":"Sonita","family":"Wiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar","family":"Lami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Rawls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2026.138703_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.addicn.2024.100155","article-title":"Xylazine is an agonist at \u03ba opioid receptors and exhibits sex-specific responses to opioid antagonism","volume":"11","author":"Bedard","year":"2024","journal-title":"Addict. Neurosci."},{"key":"10.1016\/j.neulet.2026.138703_b0010","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1021\/acschemneuro.4c00784","article-title":"Competitive Antagonism of Xylazine on alpha7 Nicotinic Acetylcholine Receptors and Reversal by Curcuminoids","volume":"16","author":"Chen","year":"2025","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neulet.2026.138703_b0015","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.7326\/M23-2001","article-title":"Xylazine Adulteration of the Heroin-Fentanyl Drug Supply: a Narrative Review","volume":"176","author":"D'Orazio","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.neulet.2026.138703_b0020","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00213-023-06390-y","article-title":"Xylazine effects on opioid-induced brain hypoxia","volume":"240","author":"Choi","year":"2023","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neulet.2026.138703_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103616","article-title":"Xylazine exacerbates fentanyl-induced respiratory depression and bradycardia","volume":"392","author":"Demery","year":"2025","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neulet.2026.138703_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.110993","article-title":"Xylazine potentiates the lethal but not the rewarding effects of fentanyl in mice","volume":"253","author":"Acosta-Mares","year":"2023","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neulet.2026.138703_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2025.174052","article-title":"Xylazine co-administration influences the rewarding properties of heroin and withdrawal in male rats","volume":"254","author":"Hochstetler","year":"2025","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.neulet.2026.138703_b0040","doi-asserted-by":"crossref","DOI":"10.1037\/pha0000670","article-title":"Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats","volume":"32","author":"Khatri","year":"2024","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.neulet.2026.138703_b0045","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.pbb.2007.09.013","article-title":"Alpha-2 agonists decrease expression of morphine-induced conditioned place preference","volume":"88","author":"Samini","year":"2008","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.neulet.2026.138703_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2024.111282","article-title":"Xylazine does not enhance fentanyl reinforcement in rats: a behavioral economic analysis","volume":"258","author":"St Onge","year":"2024","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neulet.2026.138703_b0055","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/ADM.0000000000001132","article-title":"Widespread distribution of Xylazine Detected throughout the United States in Healthcare Patient Samples","volume":"17","author":"Holt","year":"2023","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.neulet.2026.138703_b0060","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ajad.13365","article-title":"Characteristics of xylazine-related deaths in West Virginia-Xylazine-related deaths","volume":"32","author":"Sibbesen","year":"2023","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.neulet.2026.138703_b0065","first-page":"12","article-title":"Pro and anticonvulsant effects of xylazine on convulsion models in rodents","volume":"36","author":"Spinosa Hde","year":"1994","journal-title":"Vet. Hum. Toxicol."},{"key":"10.1016\/j.neulet.2026.138703_b0070","first-page":"735","article-title":"Behavioral Pharmacology of Novel \u039a Opioid Receptor Antagonists in Rats","volume":"22","author":"Page","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neulet.2026.138703_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109719","article-title":"Troriluzole inhibits methamphetamine place preference in rats and normalizes methamphetamine-evoked glutamate carboxypeptidase II (GCPII) protein levels in the mesolimbic pathway","volume":"242","author":"Wiah","year":"2023","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neulet.2026.138703_b0080","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0014-2999(82)90274-6","article-title":"Modulation of the behavioral effects of amphetamine in rats by clonidine","volume":"83","author":"Mueller","year":"1982","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neulet.2026.138703_b0085","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1196\/annals.1369.039","article-title":"Alpha-noradrenergic receptors modulate the development and expression of cocaine sensitization","volume":"1074","author":"Jim\u00e9nez-Rivera","year":"2006","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.neulet.2026.138703_b0090","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/BF00173016","article-title":"Presynaptic alpha 2A-adrenoceptors inhibit the release of endogenous dopamine in rabbit caudate nucleus slices","volume":"350","author":"Trendelenburg","year":"1994","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.neulet.2026.138703_b0095","first-page":"567","article-title":"Pharmacokinetics of ketamine and xylazine in young and old Sprague-Dawley rats","volume":"52","author":"Veilleux-Lemieux","year":"2013","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"10.1016\/j.neulet.2026.138703_b0100","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1254\/jphs.FPJ04040X","article-title":"Effects of dopamine- and serotonin-related compounds on methamphetamine-induced self-injurious behavior in mice","volume":"96","author":"Mori","year":"2004","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.neulet.2026.138703_b0105","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1038\/npp.2013.171","article-title":"\u039a opioid receptors on dopaminergic neurons are necessary for \u03ba-mediated place aversion","volume":"38","author":"Chefer","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neulet.2026.138703_b0110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0304-3940(94)90559-2","article-title":"U50,488, a \u03ba opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats","volume":"181","author":"Maisonneuve","year":"1994","journal-title":"Neurosci. Lett."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030439402600203X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030439402600203X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:29:07Z","timestamp":1793870947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030439402600203X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":22,"alternative-id":["S030439402600203X"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2026.138703","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Xylazine reduces methamphetamine-induced hyperlocomotion in rats through \u03ba-opioid and \u03b12-adrenoceptor mechanisms","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2026.138703","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"138703"}}